Altre lingue Cardiff Oncology, Inc.

Azioni

CRDF

US14147L1089

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
4,07 ^USD	+2,01%		-6,44%	+175,00%

08/04	Cardiff Oncology presenta nuovi dati preclinici al Meeting Annuale Aacr 2024 che supportano lo studio clinico di prima linea in corso sul Mcrc mutato in Ras	CI
07/03	CARDIFF ONCOLOGY, INC. : HC Wainwright conferma il rating Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update	25/04
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study	08/04
Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study	08/04
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?	26/03
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024	06/03
Sector Update: Health Care Stocks Rising Late Afternoon	01/03
Sector Update: Health Care	01/03
Cardiff Oncology Shares Jump, Discontinued Cancer Treatment Trial Shows Efficacy	01/03
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update	29/02
Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)	29/02
Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC	29/02
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC	29/02
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)	29/02
Cardiff Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference	26/02
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference	26/02
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update	22/02
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update	22/02
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research	18/01
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference	20/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Cardiff Oncology, Inc.

Azioni

CRDF

US14147L1089

Altre lingue

Filtri